- Home
- ELV vs REVBW Comparison
ELV vs REVBW Comparison
Compare ELV & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELV
- REVBW
- Stock Information
- Founded
- ELV 1944
- REVBW N/A
- Country
- ELV United States
- REVBW United States
- Employees
- ELV N/A
- REVBW 9
- Industry
- ELV Medical Specialities
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- ELV Health Care
- REVBW Health Care
- Exchange
- ELV Nasdaq
- REVBW Nasdaq
- Market Cap
- ELV N/A
- REVBW N/A
- IPO Year
- ELV N/A
- REVBW 2020
- Fundamental
- Price
- ELV $424.53
- REVBW N/A
- Analyst Decision
- ELV Buy
- REVBW
- Analyst Count
- ELV 16
- REVBW 0
- Target Price
- ELV $524.40
- REVBW N/A
- AVG Volume (30 Days)
- ELV 1.9M
- REVBW N/A
- Earning Date
- ELV 04-22-2025
- REVBW N/A
- Dividend Yield
- ELV 1.61%
- REVBW N/A
- EPS Growth
- ELV 1.82
- REVBW N/A
- EPS
- ELV 25.68
- REVBW N/A
- Revenue
- ELV $176,810,000,000.00
- REVBW N/A
- Revenue This Year
- ELV $10.34
- REVBW N/A
- Revenue Next Year
- ELV $7.41
- REVBW N/A
- P/E Ratio
- ELV $16.53
- REVBW N/A
- Revenue Growth
- ELV 3.19
- REVBW N/A
- 52 Week Low
- ELV $362.21
- REVBW N/A
- 52 Week High
- ELV $567.26
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- ELV 47.67
- REVBW N/A
- Support Level
- ELV $421.05
- REVBW N/A
- Resistance Level
- ELV $443.29
- REVBW N/A
- Average True Range (ATR)
- ELV 17.25
- REVBW 0.00
- MACD
- ELV -1.71
- REVBW 0.00
- Stochastic Oscillator
- ELV 50.23
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).